

# ASHP Statement on the Pharmacist's Role with Respect to Drug Delivery Systems and Administration Devices

Technological advances in drug delivery systems and administration devices frequently enable improved control of drug administration. Such advances may offer numerous potential benefits to patients, including improved therapeutic outcomes in disease management, improved patient compliance with drug regimens, and greater efficiency and economy in disease therapy. These advances constitute an important aspect of pharmaceutical knowledge and are routinely incorporated into pharmacy practice as they occur.

A drug delivery system is defined as one in which a drug (one component of the system) is integrated with another chemical, a drug administration device, or a drug administration process to control the rate of drug release, the tissue site of drug release, or both. A drug administration device is an apparatus that is used for introducing a drug to the body or controlling its rate of introduction. Drug delivery systems include (but are not limited to) osmotic pumps, thermal isolation, transdermal patches, liposomal encapsulation, iontophoresis, phonophoresis, magnetic migration, and implantation. Drug administration devices include (but are not limited to) mechanical (e.g., balloon-driven), gravity-driven, and electromechanical pumps. Some of the latter are portable, implantable, computer controlled, or patient controlled. Some enable the simultaneous infusion of multiple drugs. Drug administration control devices include plasma concentration monitoring and administration rate monitoring devices, which incorporate computers.

Pharmacists bear a substantial responsibility for ensuring optimal clinical outcomes from drug therapy and are suited by education, training, clinical expertise, and practice activities to assume responsibility for the professional supervision of drug delivery systems and administration devices. As a natural extension of efforts to optimize drug use, pharmacists should participate in organizational and clinical decisions with regard to these systems and devices. Some decisions and activities in which pharmacists should participate follow. Others may be appropriate as well.

1. Research and development of innovative drug delivery systems and administration devices.
2. Evaluation and research to determine the direct and comparative efficacy, safety, and cost-effectiveness of specific drug delivery systems and administration devices.
3. In conjunction with pharmacy and therapeutics committees (or other appropriate medical staff committees), decisions to choose or exclude particular drug delivery systems and administration devices for use in specific organizational settings.
4. Development of organization-specific policies and procedures regarding the acquisition, storage, distribution, use, maintenance, and ongoing product quality control of drug delivery systems and administration devices.
5. Choice of a particular drug delivery system or administration device for use in a specific patient's drug therapy.
6. Direct communication with patients to instruct them in the use of such systems and devices and to gather information necessary to monitor the outcome of their therapy.
7. Monitoring of the ongoing clinical effectiveness and suitability of specific drug delivery systems or administration devices with respect to specific patients and the communication of clinically relevant observations and recommendations to prescribers and other health professionals involved in the patients' care.

Failures or malfunctions of drug administration devices may lead to patient harm. Reports of such problems should be made in accordance with the provisions of the Safe Medical Devices Act of 1990 (PL 101-629).

## Recommendations for Additional Reading

- Acevedo ML. Electronic flow control. *NITA*. 1983; 6: 105-6.
- Akers MJ. Current problems and innovations in intravenous drug delivery. Considerations in using the i.v. route for drug delivery. *Am J Hosp Pharm*. 1987; 44:2528-30.
- Alexander MR. Current problems and innovations in intravenous drug delivery. Developing and implementing a contract for electronic infusion devices. *Am J Hosp Pharm*. 1987; 44:2553-6.
- Anderson RW, Cohen JE, Cohen MR, et al. Hospital pharmacy symposium on new concepts in parenteral drug delivery. *Hosp Pharm*. 1986; 21:1033-55.
- Baharloo M. Iontophoresis and phonophoresis: a role for the pharmacist. *Hosp Pharm*. 1987; 22:730-1.
- Block LH, Shukla AJ. Drug delivery in the 1990s. *US Pharm*. 1986; 11(Oct):51-6, 58.
- Boothe CD, Talley JR. Mechanical and electronic intravenous infusion devices. Part 1. *Infusion*. 1986; 10:6-8.
- Chandrasekaran SK, Benson H, Urquhart J. Methods to achieve controlled drug delivery, the biomedical engineering approach. In: Robinson JR, ed. Sustained and controlled release drug delivery systems. New York: Marcel Dekker; 1978:557-93.
- Colangelo A. Current problems and innovations in intravenous drug delivery. Drug preparation techniques for i.v. drug delivery systems. *Am J Hosp Pharm*. 1987; 44:2550-3.
- Davis SR. Latest developments in drug delivery systems—abstracts. *Hosp Pharm*. 1987; 22:890-908.
- Goodman MS, Wickham R. Venous access devices: oncology nurse overview. *Hosp Pharm*. 1985; 20:495-511.
- Holm A, Campbell N. Role of institutional review boards in facilitating research, marketing of drugs and devices, and protecting human subjects. *Drug Dev Ind Pharm*. 1985; 11:1-12.
- Juliano RL. Drug delivery systems. New York: Oxford University Press; 1980.
- Kelly WN, Christensen LA. Selective patient criteria for the use of electronic infusion devices. *Am J IV Ther Clin Nutr*. 1983; 10(Mar):18, 19, 21, 25, 26, 29.

- Kirschenbaum B, Klein S. Pharmacy-coordinated infusion device evaluation. *Am J Hosp Pharm.* 1984; 41:1181–3.
- Leff RD. Current problems and innovations in intravenous drug delivery. Features of i.v. devices and equipment that affect i.v. drug delivery. *Am J Hosp Pharm.* 1987; 44:2530–3.
- Longer MA, Robinson JR. Sustained-release drug delivery systems. In: Gennaro AR, ed. Remington's pharmaceutical sciences. Easton, PA: Mack Publishing Company; 1985:1644–61.
- McFarlane AE. Role for pharmacists in the provision of medical devices. *Aust J Hosp Pharm.* 1986; 16:78.
- Mutschler E. Now and future of drug delivery systems. *Pharm Tech.* 1983(Suppl); 7:13–5.
- Nahata MC. Current problems and innovations in intravenous drug delivery. Effect of i.v. drug delivery systems on pharmacokinetic monitoring. *Am J Hosp Pharm.* 1987; 44:2538–42.
- Piccoro JJ Jr. Current problems and innovations in intravenous drug delivery. Development of an institutional i.v. drug delivery policy. *Am J Hosp Pharm.* 1987; 44:2557–9.
- Polack AE, Roberts MS. Drug delivery systems. *Med J Aust.* 1986; 144:311–4.
- Rapp RP. Current problems and innovations in intravenous drug delivery. Considering product features and costs in selecting a system for intermittent i.v. drug delivery. *Am J Hosp Pharm.* 1987; 44:2533–8.
- Reilly KM. Current problems and innovations in intravenous drug delivery. Problems in administration techniques and dose measurement that influence accuracy of i.v. drug delivery. *Am J Hosp Pharm.* 1987; 44:2545–50.
- Reiss RE. Volumetric IV pumps. *Pharm Tech.* 1983(Suppl); 7:46–9.
- Self TH, Brooks JB, Lieberman P, et al. The value of demonstration and role of the pharmacist in teaching the correct use of pressurized bronchodilators. *Can Med Assoc J.* 1983; 128:129–31.
- Selton MV. Implantable pumps. *CRC Crit Rev Biomed Eng.* 1987; 14:201–40.
- Smith KL. Developments in drug delivery systems. *Hosp Pharm.* 1987; 22:905–6.
- Talley JR. Mechanical and electronic intravenous infusion devices. Part 2. *Infusion.* 1986; 10:31–4.
- Talley JR. Mechanical and electronic intravenous infusion devices. Part 3. *Infusion.* 1986; 10:58–62.
- Talsma H, Crommelin DJA. Liposomes as drug delivery systems, part I: preparation. *Pharm Tech.* 1992(Oct); 16:98, 100, 102, 104, 106.
- Urquhart J. Implantable pumps in drug delivery. *Pharm Tech.* 1983(Suppl); 7:53–4.
- Zenk KE. Current problems and innovations in intravenous drug delivery. Intravenous drug delivery in infants with limited i.v. access and fluid restriction. *Am J Hosp Pharm.* 1987; 44:2542–5.

---

*This statement was reviewed in 1998 by the Council on Professional Affairs and by the ASHP Board of Directors and was found to still be appropriate.*

Approved by the ASHP Board of Directors, November 18, 1992, and the ASHP House of Delegates, June 9, 1993. Revised by the ASHP Council on Professional Affairs. Supersedes a previous version approved by the ASHP House of Delegates on June 5, 1989, and the ASHP Board of Directors on November 16, 1988.

Copyright © 1993, American Society of Hospital Pharmacists, Inc. All rights reserved.

The bibliographic citation for this document is as follows: American Society of Hospital Pharmacists. ASHP statement on the pharmacist's role with respect to drug delivery systems and administration devices. *Am J Hosp Pharm.* 1993; 50:1724–5.